# Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

> **NCT00246402** · NA · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 30 (—)

## Conditions studied

- Insulin Resistance
- Cardiovascular Diseases
- Heart Diseases
- HIV Infections
- Hypertriglyceridemia
- Hyperlipidemia

## Interventions

- **DRUG:** Acipimox

## Key facts

- **NCT ID:** NCT00246402
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 30 (—)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246402, "Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00246402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*